Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

Marcel van den Brink, MD, PhD

Medical Oncologist, Head of the Division of Hematologic Oncology and the Alan N. Houghton Chair


Physician-scientist Marcel R. M. van den Brink studies the immunology of bone marrow transplantation. His expertise is in allogeneic (donor-provided) blood stem cell transplantation for adult cancer patients. Allogeneic hematopoietic stem cell transplantation (HSCT) is a therapy for a variety of malignancies, including leukemias, lymphomas and myeloma. Several complications limit its use including relapse of malignancy, graft versus host disease, and prolonged immune depletion caused by the conditioning required for successful transplantation – all of which can lead to increased morbidity and mortality after allo-HSCT. His laboratory uses murine HSCT models to study clinically important problems in HSCT and to test novel therapeutic strategies which can be translated into clinical practice. Van den Brink’s major projects include strategies to enhance post-transplant immune reconstitution, the role of T cells in graft-versus-host-disease and graft-versus-tumor activity.

Education & Training

  • Universiteit Leiden, South Holland, MD, PhD
  • Duke University Medical Center, Durham, NC, Residency
  • Beth Israel Deaconess Medical Center, Boston, MA, Fellowship

Awards & Honors

  • 2013: The Association of American Physicians, elected member
  • 2004: American Society for Clinical Investigation, elected member
  • 2000: Damon Runyon Scholar Award of the Cancer Research Fund; V Foundation for Cancer Research Scholarship
  • 1999: Amy Strelzer Manasevit Scholar Award of the National Marrow Donor Program
  • 1996: Physician Scientist Award of the Howard Hughes Medical Institute